Bruce Booth Sells Shares in Kymera Therapeutics
Bruce Booth sold shares of Kymera Therapeutics, totaling $65.1 million.
Key Points
- Bruce Booth sold 548,321 shares of Kymera Therapeutics on June 25, 2026, at an average price of $118.76 per share.
- Shares of Kymera Therapeutics traded near $99.87 on Friday, with a market cap of approximately $8.18 billion.
- FMR LLC increased its stake in Kymera by 2.77 million shares, now holding nearly 11.7 million shares valued at $974.5 million.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Bruce Booth, a key insider, sold 548,321 shares of Kymera Therapeutics, Inc. (NasdaqGM: KYMR) on June 25, 2026. The shares were sold at an average price of $118.76 each, totaling about $65.1 million. This transaction was planned under a Rule 10b5-1 trading plan.
Other Institutional Activity in Kymera Therapeutics
FMR LLC increased its holdings in Kymera by 2,771,376 shares, bringing its total to nearly 11.7 million shares valued at about $974.5 million. Meanwhile, T. Rowe Price Investment Management, Inc. significantly boosted its position by 4,835,252 shares, resulting in a total of approximately 5.47 million shares worth $455.2 million. Baker Bros. Advisors LP and Avoro Capital Advisors LLC maintained their existing positions without any changes.
Kymera Therapeutics, Inc. Stock Down 8.5%
Shares of Kymera Therapeutics traded near $99.87 on Friday. The company has a market capitalization of roughly $8.18 billion. It has no meaningful P/E ratio because it isn't currently profitable, with a forward P/E of -22.89. The stock has a 52-week range between $36.65 and $105.00. Its 50-day moving average stands at $83.06, and the 200-day moving average is $73.55.
$KYMR stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Kymera Therapeutics, Inc.
On June 25, 2026, Bruce Booth executed a planned sale of 548,321 shares at $118.76 per share. On the same day, Noah Goodman, Chief Business Officer, sold 5,000 shares at $114.00 per share and bought 5,000 shares at $21.05 per share outside of a trading plan. Additionally, Gorjan Hrustanovic acquired 6,068 shares on June 24, 2026.
Analysts Set New Price Targets
On June 25, 2026, BTIG reiterated its 'buy' rating for Kymera Therapeutics with a price target of $134. Earlier, Canaccord Genuity initiated coverage with a 'buy' rating and a $106 target on May 6, 2026. The consensus among 21 analysts is a 'strong buy' with an average price target of $119.19.
About Kymera Therapeutics
Kymera Therapeutics, Inc., headquartered in Watertown, Massachusetts, is a biopharmaceutical company focused on developing small molecule therapeutics that degrade disease-causing proteins. The company is involved in various clinical trials, including KT-621 for conditions like atopic dermatitis and KT-579 for autoimmune diseases. With a strategic alliance with Sanofi, Kymera aims to advance its IRAK4 program for immunology-related conditions.
Bottom Line
Bruce Booth's planned sale of Kymera Therapeutics shares underscores the insider activity within the company. Investors closely watch these transactions for potential insights, though they don't necessarily indicate a change in the company's prospects. As always, insider sales are part of the regular trading landscape and may not reflect the current outlook or performance of the company.
Get Kymera Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $KYMR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.